Zobrazeno 1 - 10
of 22
pro vyhledávání: '"R. F. Soll"'
Autor:
R F Soll
Publikováno v:
Journal of Perinatology. 27:S21-S25
The following is an overview of the evidence evaluating the risks and benefits of noninvasive methods of ventilation in premature infants. This evidence is taken from a variety of reviews in the Cochrane Library that address the issue of continuous d
Autor:
R F Soll
Publikováno v:
Journal of Perinatology. 26:S38-S42
Experimental work in animal models suggests that ventilation strategies using high frequency oscillatory ventilation or high frequency jet ventilation hold great promise in the prevention of lung injury in preterm infants. However, clinical trials of
Autor:
R. F. Soll
Publikováno v:
Acta Paediatrica. 92:886-888
UNLABELLED Postnatal corticosteroids may prevent chronic lung disease in ventilated very low birthweight infants. However, concern regarding serious neurodevelopmental consequences of therapy has led to strong recommendations to curtail use of this t
Publikováno v:
Neonatologie Scan. :24-25
Autor:
J. D. Horbar, R. F. Soll, H. Schachinger, G. Kewitz, H. T. Versmold, W. Lindner, G. Duc, D. Mieth, O. Linderkamp, E. P. Zilow, P. Lemburg, V. Von Loewenich, M. Brand, I. Minoli, G. Moro, K. P. Riegel, R. Roos, L. Weiss, J. F. Lucey
Publikováno v:
European Journal of Pediatrics. 149:416-423
We performed a multicenter prospective randomized controlled trial to determine the efficacy and safety of the surfactant preparation, Survanta (Abbott Laboratories, Chicago, USA), for 750–1750 g infants with idiopathic respiratory distress syndrom
Publikováno v:
The Cochrane database of systematic reviews. (4)
Respiratory distress syndrome (RDS) is a significant cause of morbidity and mortality in preterm infants. RDS is caused by a deficiency, dysfunction, or inactivation of pulmonary surfactant. Numerous surfactants of either animal extract or synthetic
Autor:
G K, Suresh, R F, Soll
Publikováno v:
Annals of the Academy of Medicine, Singapore. 32(3)
Exogenous surfactant therapy has an established role in the management of neonatal respiratory distress syndrome (RDS). This article summarises the current evidence on surfactant therapy. The use of surfactant for the treatment or prophylaxis of neon
Publikováno v:
The Cochrane database of systematic reviews. (2)
Both early and prophylactic surfactant replacement therapy compared with later selective surfactant administration reduces mortality and pulmonary complications in ventilated infants with respiratory distress syndrome (RDS). Continuous distending pre
Autor:
R F, Soll, C J, Morley
Publikováno v:
The Cochrane database of systematic reviews. (2)
Clinical trials have proven that surfactant therapy is effective in improving the immediate need for respiratory support and the clinical outcome of premature newborns (Soll 1992, Jobe 1993). Trials have studied a wide variety of surfactant preparati
Autor:
J D, Horbar, J, Rogowski, P E, Plsek, P, Delmore, W H, Edwards, J, Hocker, A D, Kantak, P, Lewallen, W, Lewis, E, Lewit, C J, McCarroll, D, Mujsce, N R, Payne, P, Shiono, R F, Soll, K, Leahy, J H, Carpenter
Publikováno v:
Pediatrics. 107(1)
To make measurable improvements in the quality and cost of neonatal intensive care using a multidisciplinary collaborative quality improvement model.Interventional study. Patient demographic and clinical information for infants with birth weight 501